Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ ...

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its ...

Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...

Caribou Biosciences is shutting down after failing to raise the money necessary to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.

When raising capital for a biotech with a consumer business, the same company can look attractive to biotech and commercial ...

Clinical trials are a key driver of biotech stocks. Every new therapy must pass through a series of testing, Phase 1, Phase 2 ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

While biotech increasingly adopts AI for R&D, manufacturing bottlenecks constrain health innovation. AI and robotics have the ...

Nurse.org interviewed Keith Dawson, DNP, MS, RN, Senior Director, Global Population Science, Genentech (A Member of the Roche ...

Session: Advances in Oncology Panel Presenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin Date/time: ...

Dutch haul comes despite European drugmakers and investors warning the region is losing ground.